Media ReleasesNext Science

View All Next Science News


Next Science - Potential Anti-Inflammatory Benefit For XPERIENCE


Highlights:

  • Dr Andrew B. Wickline, MD, FAAOS has released the findings of a pilot study which demonstrated 54% lower inflammation within 14 days compared to the common reference standard.
  • The study was a 60-patient double-arm study incorporating Dr. Wickline’s current strategies to reduce inflammation, with the first group of patients receiving a 3-minute sterile dilute iodine lavage (current industry standard), and, the second group of patients receiving Next Science’s advanced surgical irrigation solution, XPERIENCE™.
  • The study concluded that the lower inflammation outcome, even compared to Dr Wickline’s low baseline inflammation rate, resulted in:
         • 5-degree increase in range of motion throughout the study period
         • 10%-20% improvement in pain score throughout the study period
         • 18% lower opioid usage for pain relief at day 7 improving to 70% less usage at day 42, with XPERIENCE™ patients eliminating opiate use in half the time of control patients
  • The significant swelling reduction at several time points is statistically significant. The findings are encouraging and warrant a further multicentre study with a larger patient cohort and additional surgeons.

Sydney Australia Wednesday, 9 August 2023: Next Science Limited (ASX: NXS) (Next Science or Company), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, is pleased to announce the presentation of a study into mitigating inflammation post Total Knee Arthroplasty (TKA).

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?